UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

October 728, 2011

Date of Report (Date of earliest event reported)

Poniard Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)


Washington	0-16614	91-1261311
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

750 Battery Street, Suite 330, San Francisco, California				94111
(Address of principal executive offices)				(Zip Code)

750 Battery Street, Suite 330, San Francisco, CA 94111

(Address of principal executive offices) (Zip Code)

(650) 583-3774

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

x¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 82 – ~~Other~~Financial ~~Events~~Information

Item 82.0102. ~~Other~~Results ~~Events~~of Operations and Financial Condition.

~~On October 7,~~The ~~2011, Poniard Pharmaceuticals, Inc. (the “~~Company” ~~or “Poniard”)~~ issued a press release ~~announcing~~dated ~~that~~October 28, ~~the~~2011, ~~Securities~~announcing ~~and~~its ~~Exchange~~financial ~~Commission~~results ~~had~~for ~~declared effective~~ the ~~Company’s~~quarter ~~Registration~~and ~~Statement~~nine ~~on Form~~months ~~S-4~~ended ~~relating to the previously announced proposed merger between Poniard and ALLOZYNE~~September 30, ~~Inc~~2011. ~~(“Allozyne”).~~ The ~~boards~~full oftext ~~directors~~ of ~~both companies have previously approved~~ the ~~merger~~press ~~transaction,~~release ~~which~~ is ~~subject to customary closing~~set ~~conditions,~~forth ~~including~~in ~~approval~~Exhibit by99.1 ~~Allozyne’s~~attached ~~and Poniard’s respective stockholders and receipt of approval for listing of the combined company’s common stock on The Nasdaq Capital Market~~hereto. The ~~special~~press ~~meeting~~release ofshould ~~Poniard’s shareholders~~be ~~regarding,~~read ~~among~~in ~~other~~conjunction ~~things,~~with the ~~approval~~note ofregarding ~~the~~forward-looking ~~proposed merger transaction~~statements, ~~will~~which beis ~~held~~included atin ~~9:00 a.m. on November 21, 2011, at~~ the ~~offices~~text of ~~Bay~~the ~~City~~press ~~Capital, located at 750 Battery Street, Suite 400, San Francisco, California 94111~~release.

~~Investors~~The ~~and~~information ~~security~~in ~~holders~~this ofItem 2.02 ~~Poniard~~ and ~~Allozyne~~attached ~~are~~as ~~urged~~Exhibit 99.1 to ~~read~~this ~~the~~Report ~~proxy~~will ~~statement/prospectus/consent solicitation~~not ~~(including~~be ~~any~~treated ~~amendments~~as or“filed” ~~supplements~~for to the purposes ~~proxy~~of ~~statement/prospectus/consent~~Section 18 ~~solicitation) that is part~~ of ~~Poniard’s~~the ~~Registration~~Securities ~~Statement~~Exchange onAct ~~Form~~of ~~S-4 when it becomes available~~1934, ~~because~~as itamended ~~will~~(the ~~contain~~“Exchange ~~important~~Act”), ~~information about~~or ~~Poniard,~~otherwise ~~Allozyne~~subject ~~and~~to the ~~proposed~~liabilities ~~transaction.~~of ~~Investors~~that ~~and~~section. ~~security~~This ~~holders~~information ~~of Poniard~~ will not be ~~able~~incorporated toby ~~obtain~~reference ~~free~~into ~~copies~~any offiling ~~the~~under ~~definitive proxy statement/prospectus/consent solicitation through~~ the ~~website maintained by the SEC at~~ ~~www.sec.gov.~~Securities ~~Free~~Act ~~copies~~ of ~~the definitive proxy statement/prospectus/consent solicitation~~1933, ~~when~~as ~~it becomes available~~amended, ~~and~~or ~~Poniard’s~~into ~~other~~another ~~filings~~filing ~~with~~under the ~~SEC~~Exchange ~~also may be obtained by contacting Poniard Pharmaceuticals~~Act, ~~Inc.,~~unless ~~750~~that ~~Battery Street,~~filing ~~Suite~~expressly ~~330,~~incorporates ~~San~~this ~~Francisco,~~information CAby ~~94111, or accessed via Poniard’s website at www~~reference.~~poniard.com.~~

Poniard, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from its shareholders in favor of the proposed transaction. Information regarding the directors and executive officers of Poniard and their interests in the proposed transaction will be available in the proxy statement/prospectus/consent solicitation.

A copy of the Company’s press release is attached hereto as Exhibit 99.1 and incorporated herein by reference, specifically including the cautionary note regarding forward-looking statements contained in the press release.

Section 9 – Financial Statements and Exhibits

Item 9.01.		Financial Statements and Exhibits.
(d)		Exhibits.
		99.1 – Press release dated October 7, 2011

Item 9.01.

Financial Statements and Exhibits.

(d)

Exhibits.

99.1 - Press release dated October 28, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	~~Poniard Pharmaceuticals, Inc.~~	Poniard Pharmaceuticals, Inc.
Dated: October 12, 2011	By:	/s/ MICHAEL K. JACKSON
Dated: November 2, 2011		By:	/s/ MICHAEL K. JACKSON
		Name: Michael K. Jackson
		Name:	Michael K. Jackson
		Title: Interim Chief Financial Officer
		Title:	Interim Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EXHIBIT INDEX

	Exhibit No.	Description
ExhibitNo.	Description
99.1	~~99.1~~Press Release dated October 28, 2011	~~Press Release dated October 7, 2011~~

Filing Compare · PONIARD PHARMACEUTICALS, INC.